Mirikizumab Improves Fatigue Abdominal Pain and Stool Frequency in Crohn’s Disease
Results presented at UEG Week 2025 in Berlin underscore the durable efficacy of mirikizumab in reducing symptom burden and improving quality of life in patients with Crohn’s disease.
 
										







